These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 25358867

  • 1. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
    Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D.
    Int J Clin Pract; 2014 Dec; 68(12):1514-22. PubMed ID: 25358867
    [Abstract] [Full Text] [Related]

  • 2. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 4. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E, Correll CU, Mao L, Starr HL, Alphs L.
    CNS Spectr; 2016 Dec 01; 21(6):466-477. PubMed ID: 27629292
    [Abstract] [Full Text] [Related]

  • 5. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA.
    Schizophr Res; 2005 Sep 15; 77(2-3):129-39. PubMed ID: 15913962
    [Abstract] [Full Text] [Related]

  • 6. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 15; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 7. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia.
    Rui Q, Wang Y, Liang S, Liu Y, Wu Y, Wu Q, Nuamah I, Gopal S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug 04; 53():45-53. PubMed ID: 24576532
    [Abstract] [Full Text] [Related]

  • 8. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.
    Int Clin Psychopharmacol; 2014 Jan 04; 29(1):45-55. PubMed ID: 24113628
    [Abstract] [Full Text] [Related]

  • 9. Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
    Misawa F, Fujii Y, Takeuchi H.
    J Clin Psychiatry; 2022 Aug 03; 83(5):. PubMed ID: 35921512
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
    Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M.
    Int J Neuropsychopharmacol; 2012 Feb 03; 15(1):107-18. PubMed ID: 21777507
    [Abstract] [Full Text] [Related]

  • 11. Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database.
    Boels D, Mahé J, Olry A, Citterio-Quentin A, Moragny J, Jolliet P.
    Clin Toxicol (Phila); 2021 Sep 03; 59(9):786-793. PubMed ID: 33555955
    [Abstract] [Full Text] [Related]

  • 12. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L.
    BMC Psychiatry; 2011 May 10; 11():79. PubMed ID: 21569242
    [Abstract] [Full Text] [Related]

  • 13. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.
    Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L.
    J Affect Disord; 2016 Mar 15; 193():381-90. PubMed ID: 26802315
    [Abstract] [Full Text] [Related]

  • 14. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR, Maia-Lopes S, Goswami P, Bereza BG, Van Impe K.
    J Med Econ; 2016 Sep 15; 19(9):913-21. PubMed ID: 27124697
    [Abstract] [Full Text] [Related]

  • 15. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
    Alphs L, Bossie C, Mao L, Lee E, Starr HL.
    Early Interv Psychiatry; 2018 Feb 15; 12(1):55-65. PubMed ID: 26403322
    [Abstract] [Full Text] [Related]

  • 16. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K, Pan X, Wang R, Yang E, Benson C.
    Curr Med Res Opin; 2016 Nov 15; 32(11):1873-1881. PubMed ID: 27479694
    [Abstract] [Full Text] [Related]

  • 17. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.
    Pharmacoeconomics; 2016 Apr 15; 34(4):363-91. PubMed ID: 26883132
    [Abstract] [Full Text] [Related]

  • 18. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC, Reggiori A, Paletta S, Di Pace C, Altamura AC.
    Expert Opin Drug Saf; 2017 Mar 15; 16(3):365-379. PubMed ID: 28140680
    [Abstract] [Full Text] [Related]

  • 19. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A, Caspi A, Bergmans P, Cherubin P, Keim S, Lara E, Pinchuk I, Schuepbach D, Suleman S, Hargarter L.
    Psychopharmacology (Berl); 2017 Jan 15; 234(1):3-13. PubMed ID: 27815602
    [Abstract] [Full Text] [Related]

  • 20. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.
    BMC Psychiatry; 2011 Feb 07; 11():21. PubMed ID: 21299844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.